恒瑞医药：SHR-8068注射液、阿得贝利单抗注射液、贝伐珠单抗注射液临床试验获批

Group 1 - The company, Heng Rui Medicine (600276.SH), announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have received approval from the National Medical Products Administration (NMPA) for clinical trials of SHR-8068 injection, Adalimumab injection, and Bevacizumab injection [1]